Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Accured Expenses (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Change in Accured Expenses readings, the most recent being $38.1 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 857.26% to $38.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.8 million, a 601.07% increase, with the full-year FY2025 number at $82.8 million, up 601.07% from a year prior.
  • Change in Accured Expenses hit $38.1 million in Q4 2025 for Amicus Therapeutics, up from $30.6 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $38.1 million in Q4 2025 to a low of -$40.2 million in Q1 2021.
  • Median Change in Accured Expenses over the past 5 years was $7.3 million (2021), compared with a mean of $5.8 million.
  • Biggest five-year swings in Change in Accured Expenses: surged 1204.27% in 2021 and later plummeted 33904.17% in 2024.
  • Amicus Therapeutics' Change in Accured Expenses stood at $29.5 million in 2021, then crashed by 207.95% to -$31.8 million in 2022, then skyrocketed by 125.42% to $8.1 million in 2023, then tumbled by 162.23% to -$5.0 million in 2024, then skyrocketed by 857.26% to $38.1 million in 2025.
  • The last three reported values for Change in Accured Expenses were $38.1 million (Q4 2025), $30.6 million (Q3 2025), and $10.4 million (Q2 2025) per Business Quant data.